Scilex Holding Adjusts Record Date for Upcoming Stock Dividend

Scilex Holding Company Updates Dividend Record Date

Scilex Holding Company, a pioneering firm in the non-opioid pain management sector, has announced a significant adjustment to its preferred stock dividend schedule. Originally set for November 7, 2024, the record date for this anticipated dividend has now been moved to January 28, 2025. This change comes as part of Scilex's ongoing efforts to optimize its shareholder communications and financial strategies.

Importance of the Dividend Announcement

The decision to alter the record date reflects Scilex's commitment to maintaining clear and timely information to its stockholders and securityholders about the company's financial decisions. The anticipated dividend is closely tied to the company's strong performance in developing and commercializing non-opioid solutions for treating acute and chronic pain, particularly through its subsidiary Semnur Pharmaceuticals.

About Scilex Holding Company

Scilex Holding Company is dedicated to innovating in the pain management space. Their product offerings include ZTlido® for neuropathic pain, ELYXYB® for migraines, and Gloperba® for gout management. These products are part of Scilex's mission to cater to unmet medical needs while bolstering market opportunities in non-opioid treatments.

Details on the Dividend and Future Payments

The Board of Directors has emphasized that while the new record date is now set, they retain the option to further modify this date if necessary. Following the record date, the payment date for the dividend will be clarified through subsequent resolutions. This thoughtful strategic approach underlines Scilex's intent to enhance shareholder value and ensure that investors remain aligned with the company's growth trajectory.

Innovations in Pain Management

Scilex is not just about dividends; its pipeline is robust with three notable product candidates aimed at improving patient outcomes. Among these is SP-102, a unique viscous gel formulation targeting sciatica that has successfully passed Phase 3 studies. SP-103 is another promising candidate, purpose-built for acute pain treatments and currently in Phase 2 trials.

Expanding Market Opportunities

Scilex's focus extends beyond traditional pain management, as the company is also forming joint ventures to explore treatments for neurodegenerative and cardiometabolic diseases. These initiatives present exciting opportunities not only for Scilex but for the wider pharmaceutical landscape. As they continue to innovate, their role as a key player in pain management becomes even more pronounced.

Company Presence and Engagement

Headquartered in Palo Alto, California, Scilex is well-placed in a region known for its technological and medical advancements. The company engages proactively with investors and media, fostering transparency and communication. This commitment to interaction is evident in their various channels, including their corporate website and social media platforms.

Frequently Asked Questions

What is the new record date for the dividend?

The new record date for Scilex's preferred stock dividend is January 28, 2025.

What products does Scilex hold?

Scilex offers several innovative products including ZTlido®, ELYXYB®, and Gloperba® among others.

What developments are Scilex pursuing?

Scilex is pursuing multiple clinical trials and product developments aimed at both pain management and neurodegenerative diseases.

Where is Scilex located?

Scilex Holding Company is headquartered in Palo Alto, California.

Who can benefit from Scilex's products?

Patients suffering from acute and chronic pain, including those with neurological conditions, can potentially benefit from Scilex's innovative therapies.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.